Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency-Reference-Cited by-同舟云学术

Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency

Published:2022-10-03 Issue:2 Volume:89 Page:762-772
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Maillard Maud¹,Launay Manon²^ORCID,Royer Bernard³^ORCID,Guitton Jérôme⁴,Gautier‐Veyret Elodie⁵^ORCID,Broutin Sophie⁶,Tron Camille⁷,Le Louedec Félicien¹,Ciccolini Joseph⁸,Richard Damien⁹,Alarcan Hugo¹⁰,Haufroid Vincent¹¹¹²,Tafzi Naïma¹³,Schmitt Antonin¹⁴^ORCID,Etienne‐Grimaldi Marie‐Christine¹⁵,Narjoz Céline¹⁶,Thomas Fabienne¹^ORCID,

Affiliation:

1. Laboratoire de Pharmacologie, Institut Claudius Regaud, IUCT‐Oncopole et Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037 Université Paul Sabatier Toulouse France

2. Laboratoire de Pharmacologie et Toxicologie CHU de Saint‐Etienne Saint‐Etienne France

3. Laboratoire de Pharmacologie Clinique et Toxicologie CHU Besançon and Univ. Bourgogne Franche‐Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte‐Greffon‐Tumeur/Ingénierie Cellulaire et Génique Besançon France

4. Laboratoire de Pharmacologie Toxicologie CHU de Lyon Lyon France

5. Laboratoire de Pharmacologie, Pharmacogénétique et Toxicologie CHU Grenoble‐Alpes et Université Grenoble‐Alpes, laboratoire HP2, INSERM U1300 Grenoble France

6. Département de Biologie et Pathologie Médicale Service de Pharmacologie, Gustave Roussy Villejuif France

7. Laboratoire de pharmacologie CHU de Rennes Université de Rennes, CHU de Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085 Rennes France

8. SMARTc Unit, CRCM Inserm U1068 et Laboratoire de Pharmacocinétique CHU La Timone Marseille France

9. Laboratoire de Pharmacologie et Toxicologie CHU de Clermont‐Ferrand Clermont‐Ferrand France

10. Service de Biochimie et Biologie Moléculaire CHRU de Tours Tours France

11. Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Clinical and Experimental Research Institute (IREC) Université catholique de Louvain Brussels Belgium

12. Clinical Chemistry Department Cliniques Universitaires Saint‐Luc Brussels Belgium

13. INSERM, Université de Limoge, Service de Pharmacologie et Toxicologie, CHU de Limogess, U1248 IPPRITT Limoges France

14. Service Pharmacie, Centre Georges‐François Leclerc et INSERM U1231 Université de Bourgogne Dijon France

15. Laboratoire d'Oncopharmacologie Centre Antoine Lacassagne Nice France

16. Assistance Publique des Hôpitaux de Paris Hôpital européen Georges‐Pompidou, Service de biochimie Paris France

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15536

Reference38 articles.

1. Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France

2. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil

3. Population study of dihydropyrimidine dehydrogenase in cancer patients.

4. HAS‐Santé.Dihydropyrimidine dehydrogenase deficiency testing to prevent fluoropyrimidines‐associated severe toxicities.2018.https://www.has-sante.fr/jcms/c_2891090/en/screening-for-dihydropyrimidine-dehydrogenase-deficiency-to-decrease-the-risk-of-severe-toxicities-related-to-fluoropyrimidines-5-fluorouracil-or-capecitabine-inahta-brief. Accessed September 20 2022.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Partial protein binding of uracil and thymine affects accurate dihydropyrimidine dehydrogenase (DPD) phenotyping;Journal of Pharmaceutical and Biomedical Analysis;2024-10

2. Reply to: “Is uracil enough for effective pre-emptive DPD testing?”;Clinical Chemistry and Laboratory Medicine (CCLM);2024-08-15

3. Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis;Clinical Chemistry and Laboratory Medicine (CCLM);2024-06-19

4. Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study;Cancer Medicine;2024-03

5. Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing;Clinical Chemistry and Laboratory Medicine (CCLM);2024-01-11